Neptune (NEPT) and Ingenutra Enter Exclusive Worldwide Agreement for MaxSimil
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT) through its wholly-owned subsidiary, Biodroga Nutraceutical Inc., has signed an exclusive, worldwide and royalty bearing commercial agreement with Ingenutra Inc. for its patented and clinically studied MaxSimil specialty ingredient. Designed as a unique delivery system, MaxSimil allows for enhanced bioavailability and absorption of lipid based and lipid soluble nutraceuticals ingredients such as omega-3 fish oils, vitamin A, D, K and E, CoQ10 and others.
The agreement allows Neptune to manufacture, distribute and sell MaxSimil in the nutraceutical field worldwide. The terms also cover potential collaboration between both companies on clinical trials. The agreement is valid until 2028 and supersedes a previous arrangement between Biodroga and Ingenutra that was limited to North America. All other terms of the agreement remain confidential.
Francois-Karl Brouillette, Vice-President Scientific Affairs of Neptune stated, "Increasing the bioavailability and absorption of EPA and DHA in a natural way is truly amazing. MaxSimil now makes it possible for everyone, including people suffering from compromised digestive health to properly assimilate their healthy fats. We are very proud to make this ingredient accessible worldwide. This is what Neptune and our industry are all about: improving the quality of life of consumers through healthy nutrition solutions."
Serge Brunet, President of Ingenutra added, "I am proud of this new partnership with Neptune. I am confident that they will provide the steppingstone that will allow the benefits of MaxSimil to be recognized worldwide through Neptune's well established and growing network".
Recently, one of Neptune's clients, XYMOGEN®, launched the MonoPure™ line of omega-3 EPA + DHA products based on Maxsimil. It is aimed at the practitioner market in the United States.
The research and development of MaxSimil was developed by a researcher at the University of Rimouski, Quebec. MaxSimil mimics the natural digestive process and delivers a patented pre-digested and absorption-ready Monoglyceride-rich Omega-3 Fish Oil. It enhances the bioavailability and absorption of Omega-3 fatty acids by applying a natural and gentle enzymatic process converting them into pre-digested natural Monoglycerides. A human pharmacokinetic study has demonstrated with statistical significance 3x greater absorption of MaxSimil EPA and DHA when compared to a regular fish oil. Furthermore, this absorption ready omega-3 supplement is an ideal solution for populations in certain age groups, taking medication or suffering from conditions compromising their digestion health and preventing them to properly digest healthy fats. MaxSimil is a 100% natural fish oil with no additives.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY), Ono Enter Settlement and License Agreement with Merck (MRK) to Resolve PD-1 Antibody Patent Litigation
- Rennova Health (RNVA) Says Genomas Subsidiary Granted Patent
- DryShips (DRYS) Acquires Its First VLGC With 5 Year Time Charter Attached to Oil Major
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!